Who is eligible for clinical trial NCT05470010?

Participants must meet protocol criteria for Cancer. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05470010 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-17

Smartphone App-Based Mindfulness Intervention for French and English Speaker Cancer Survivors (NCT05470010)

🔵 Active, Not Recruiting Observational / Diagnostic 🧠 Behavioral & Psychological Program Sponsor: Canadian Cancer Trials Group

🩺 Plain-English Summary (8th-Grade Level)

There is a need to develop, evaluate, and disseminate self-directed, easily accessible, safe, affordable, and effective psychosocial interventions to people living with cancer (PLWC) post-treatment. Smartphone app-based health interventions are an innovative way to deliver psychosocial cancer-care. The Mindfulness-Based Cancer Survivorship (MBCS) Journey app is a mobile app format of the Mindfulness-based Cancer Recovery program. In the SEAMLESS Study, the investigators aim to evaluate the MBCS Journey app (a 4 week mind-body intervention) in cancer survivors post-treatment. This is a randomized wait-list controlled trial. Participants will either be assigned into the immediate group (will receive intervention immediately after enrollment) or the waitlist group (wait for 3 months before receiving the intervention).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (9 items) and avoid the listed exclusions (4 items).

Location: Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Adult ≥ 18 years
Diagnosed with any type of cancer (stages I-IV)
Completed primary treatment (i.e. surgery, chemotherapy, radiation therapy) at least 2 weeks (14days) prior. Note: ongoing maintenance therapy, hormone-blocking therapies, intermittent bone-modifying agents, herceptin and targeted therapy with trastuzumab are not exclusionary.
Have access to a smartphone with data or wifi connection.
Willing to devote 20-30 mins of time to mindfulness practices daily during the 4-week intervention period.
Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form (e-consent) prior to enrollment in the study to document their willingness to participate.
Participant is able (i.e. sufficiently fluent) and willing to complete the MBCS Journey and outcome measures in either English or French. The baseline assessment must be completed within required timelines, prior to randomization.
In accordance with CCTG policy, protocol intervention is intended to begin within 7 calendar days of patient randomization.
Participants must be willing to complete the MBCS Journey and complete the follow-up questionnaires

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Major communication difficulties at the time of recruitment, as assessed by the research team (e.g. severe hearing impairment or cognitive impairment (score of ≤ 6; as assessed by the centre CRA using the three questions from the Brief Screen for Cognitive Impairment (BSCI)) listed in the screening CRF, which could interfere with completing the intervention and/or the questionnaires (i.e. inability to read or write)
Suffering from untreated Major Depressive Disorder or other psychiatric disorders that would interfere with participation. (Note: Participants will be referred for treatment and invited to call back once in remission).
Previous experience practicing in-person or app-based mindfulness once a week or more within the last year.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (7 Sites)

Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
BCCA - Kelowna — Kelowna, British Columbia
BCCA - Prince George — Prince George, British Columbia
BCCA - Victoria — Victoria, British Columbia
Western Manitoba Cancer Centre — Brandon, Manitoba
Horizon Health Network — Fredericton, New Brunswick
Kingston Health Sciences Centre — Kingston, Ontario

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗